Delaware legislation · 153rd General Assembly
Delaware SB120: Biomarker Testing/Insurance/Require
Status: Signed into law, September 8, 2026
AN ACT TO AMEND TITLES 18, 29, AND 31 OF THE DELAWARE CODE RELATING TO HEALTH INSURANCE.
What the bill says
An act to amend titles 18, 29, and 31 of the delaware code relating to health insurance.
From the introduced text, May 1, 2025:
AN ACT TO AMEND TITLES 18, 29, AND 31 OF THE DELAWARE CODE RELATING TO HEALTH INSURANCE. Section 1. Amend Chapter 33, Title 18 of the Delaware Code by making deletions as shown by strike through and insertions as shown by underline as follows and by redesignating accordingly: § 3370M. Biomarker testing. (a) For purposes of this section: (1) "Biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include gene mutations, characteristics of genes, and protein expression. (2) "Biomarker testing" means the analysis of an individual's tissue, blood, or other biospecimen for the presence of a biomarker. Biomarker testing includes single-analyte tests, multi-plex panel tests, protein expression, and whole exome, whole genome, and whole transcriptome sequencing. (3) "Consensus statement" means a statement that describes optimal clinical care outcomes, based on the best available evidence, for a specific clinical circumstance and is developed by an independent, multidisciplinary panel of experts using a transparent methodology and reporting structure and adhering to a conflict-of-interest policy. (4) "Nationally recognized clinical practice guideline" means an evidence-based clinical practice guideline developed by independent organizations or medical professional societies using a transparent methodology and …
Sponsors
- Spiros Mantzavinos (D, 7) · primary sponsor
- William Bush (D, 29)
- Daniel Cruce (D, 1)
- Stephanie Hansen (D, 10)
- Kyra Hoffner (D, 14)
- Raymond Seigfried (D, 5)
- John Walsh (D, 9)
- David Wilson (R, 18)
- Alonna Berry (D, 20)
- Mara Gorman (D, 23)
- Eric Morrison (D, 27)
Latest actions
- : SS 1 for SB 120 - Signed by Governor
- : SS 1 for SB 120 - Passed By House. Votes: 40 YES 1 ABSENT
- : SS 1 for SB 120 - Reported Out of Committee (Appropriations) in House with 4 On Its Merits
- : SS 1 for SB 120 - Assigned to Appropriations Committee in House
- : SS 1 for SB 120 - Reported Out of Committee (Economic Development/Banking/Insurance & Commerce) in House with 2 Favorable, 7 On Its Merits
- : SS 1 for SB 120 - Assigned to Economic Development/Banking/Insurance & Commerce Committee in House
- : SS 1 for SB 120 - Passed By Senate. Votes: 20 YES 1 ABSENT
- : SS 1 for SB 120 - Reported Out of Committee (Finance) in Senate with 4 On Its Merits
- : SS 1 for SB 120 - Assigned to Finance Committee in Senate
- : SS 1 for SB 120 - Reported Out of Committee (Banking, Business, Insurance & Technology) in Senate with 6 Favorable
Votes
- Passed (SM) (July 1, 2026): 40 yea, 0 nay, passed
- Passed (2/3) (June 10, 2026): 20 yea, 0 nay, passed
Common questions
- What is SB120?
- SB120 is a bill in the Delaware Legislature (153rd General Assembly): Biomarker Testing/Insurance/Require.
- What does SB120 do?
- In its own words: An act to amend titles 18, 29, and 31 of the delaware code relating to health insurance.
- What is the status of SB120?
- Signed into law as of September 8, 2026. Latest action: SS 1 for SB 120 - Signed by Governor (September 8, 2026).
- Who sponsored SB120?
- Spiros Mantzavinos (D, 7), with 10 co-sponsors.
- Where is the official record for SB120?
- On the Delaware Legislature website: https://legis.delaware.gov/BillDetail?LegislationId=142167
Source: official Delaware record. Tracked by Delilah, AI for legislation across all 50 states and Congress.